Enanta Pharma DEF 14A: Executive Compensation Details
Ticker: ENTA · Form: DEF 14A · Filed: Jan 27, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | DEF 14A |
| Filed Date | Jan 27, 2025 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $37,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, DEF-14A
TL;DR
Enanta Pharma's DEF 14A shows exec comp details, including equity awards for PEO.
AI Summary
Enanta Pharmaceuticals Inc. filed its DEF 14A on January 27, 2025, for the fiscal year ending September 30, 2024. The filing details executive compensation, including equity awards granted to its Principal Executive Officer (PEO) and other employees. For instance, the PEO received equity awards with a change in fair value of outstanding and unvested awards in prior years of $1,000,000 for the period of January 1, 2024, to December 31, 2024.
Why It Matters
This filing provides transparency into how Enanta Pharmaceuticals compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not contain significant new financial or operational information.
Key Numbers
- $1,000,000 — Change in Fair Value of Equity Awards (For PEO, Jan 1, 2024 - Dec 31, 2024)
Key Players & Entities
- Enanta Pharmaceuticals Inc. (company) — Filer
- 0000950170-25-009168 (filing_id) — Accession Number
- January 27, 2025 (date) — Filing Date
- September 30, 2024 (date) — Fiscal Year End
- Principal Executive Officer (PEO) (person) — Executive Role
FAQ
What was the total compensation for the Principal Executive Officer (PEO) in the fiscal year ending September 30, 2024?
The filing does not explicitly state the total compensation for the PEO for the fiscal year ending September 30, 2024, but it details changes in fair value of equity awards.
When was the DEF 14A filing submitted by Enanta Pharmaceuticals Inc.?
The DEF 14A filing was submitted on January 27, 2025.
What is the fiscal year end for Enanta Pharmaceuticals Inc. as reported in this filing?
The fiscal year end for Enanta Pharmaceuticals Inc. is September 30.
What type of compensation is detailed in the filing regarding equity awards?
The filing details the change in fair value of outstanding and unvested equity awards granted in prior years, as well as equity awards granted in the covered year.
What is the SIC code for Enanta Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Enanta Pharmaceuticals Inc. is 2834 (Pharmaceutical Preparations).
Filing Stats: 4,808 words · 19 min read · ~16 pages · Grade level 10.7 · Accepted 2025-01-27 16:00:56
Key Financial Figures
- $37,500 — ments, which are not expected to exceed $37,500, in total. Who can help answer my que
Filing Documents
- enta-20250127.htm (DEF 14A) — 3016KB
- img217881502_0.jpg (GRAPHIC) — 23KB
- img217881502_1.jpg (GRAPHIC) — 23KB
- img217881502_2.jpg (GRAPHIC) — 23KB
- img217881502_3.jpg (GRAPHIC) — 23KB
- img217881502_4.jpg (GRAPHIC) — 23KB
- img217881502_5.jpg (GRAPHIC) — 23KB
- img217881502_6.jpg (GRAPHIC) — 23KB
- img217881502_7.jpg (GRAPHIC) — 23KB
- img217881502_8.jpg (GRAPHIC) — 23KB
- img217881502_9.jpg (GRAPHIC) — 1121KB
- img217881502_10.jpg (GRAPHIC) — 1224KB
- img217881502_11.jpg (GRAPHIC) — 906KB
- img217881502_12.jpg (GRAPHIC) — 1374KB
- img217881502_13.jpg (GRAPHIC) — 203KB
- 0000950170-25-009168.txt ( ) — 15535KB
- enta-20250127.xsd (EX-101.SCH) — 19KB
- enta-20250127_htm.xml (XML) — 286KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 32 Compensation Discussion and Analysis 32 Compensation Committee Report 45 Summary Compensation Table 46 2024 Grants of Plan-Based Awards 49 2024 Options Exercised and Stock Awards Vested 51 Outstanding Equity Awards at Fiscal 2023 Year-End 51 Potential Payments Upon Termination, Including Termination After a Change in Control Transaction 53 CEO Pay Ratio 55 Pay Versus Performance 56 DIRECTOR COMPENSATION 61 AUDIT COMMITTEE REPORT 63 STOCKHOLDER MATTERS 65 Appendix A A- 1 PROXY STATEMENT INFORMATION CONCERNING SOLICITATION AND VOTING We are soliciting proxies from our stockholders to vote at our 2025 Annual Meeting of Stockholders, or at any continuation, postponement or adjournment thereof, for the purposes discussed in this proxy statement. The annual meeting will be held virtually at 5:00 p.m. Eastern time on Thursday, March 13, 2025, at www.proxydocs.com/ENTA. For more information on how to access the virtual meeting, please visit the "Investors – 2025 Annual Meeting Materials" section of our website at www.enanta.com or contact Investor Relations at (617) 744-3848. The proxy materials, including this proxy statement and our 2024 annual report to stockholders, are being distributed and made available on the internet at the "Investors – 2025 Annual Meeting Materials" section of our website at www.enanta.com on or about January 27, 2025. This proxy statement contains important information for you to consider when deciding how to vote on the matters brought before the meeting. Please read it carefully. All references in this proxy statement to a particular year refer to our twelve-month fiscal year ended on September 30 of that year, e.g., September 30, 2024, unless the context indicates otherwise. QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Why did I receive these materials? We are soliciting proxies for our annual meeting of stockholders to be held on Thu